Pfizer Inc.
PFE
$23.49
$0.200.86%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/30/2025 | 12/31/2024 | 09/29/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.72B | 17.76B | 17.70B | 13.28B | 14.88B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.72B | 17.76B | 17.70B | 13.28B | 14.88B |
| Cost of Revenue | 2.59B | 5.74B | 4.87B | 2.77B | 3.04B |
| Gross Profit | 11.12B | 12.02B | 12.83B | 10.52B | 11.84B |
| SG&A Expenses | 2.91B | 4.74B | 3.12B | 3.56B | 3.35B |
| Depreciation & Amortization | 1.21B | 1.36B | 1.31B | 1.31B | 1.31B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.89B | 14.94B | 11.86B | 10.31B | 10.17B |
| Operating Income | 4.82B | 2.83B | 5.84B | 2.98B | 4.71B |
| Income Before Tax | 2.78B | -10.00M | 4.72B | -103.00M | 3.42B |
| Income Tax Expenses | -189.00M | -421.00M | 234.00M | -134.00M | 293.00M |
| Earnings from Continuing Operations | 2.97B | 411.00M | 4.48B | 31.00M | 3.13B |
| Earnings from Discontinued Operations | -- | 7.00M | -8.00M | 17.00M | -5.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -6.00M | -8.00M | -8.00M | -7.00M | -8.00M |
| Net Income | 2.97B | 410.00M | 4.47B | 41.00M | 3.12B |
| EBIT | 4.82B | 2.83B | 5.84B | 2.98B | 4.71B |
| EBITDA | 6.44B | 4.61B | 7.58B | 4.70B | 6.44B |
| EPS Basic | 0.52 | 0.07 | 0.79 | 0.01 | 0.55 |
| Normalized Basic EPS | 0.49 | 0.26 | 0.56 | 0.28 | 0.45 |
| EPS Diluted | 0.52 | 0.07 | 0.79 | 0.01 | 0.55 |
| Normalized Diluted EPS | 0.49 | 0.26 | 0.56 | 0.27 | 0.44 |
| Average Basic Shares Outstanding | 5.68B | 5.67B | 5.67B | 5.67B | 5.66B |
| Average Diluted Shares Outstanding | 5.71B | 5.70B | 5.71B | 5.70B | 5.70B |
| Dividend Per Share | 0.43 | 0.42 | 0.42 | 0.42 | 0.42 |
| Payout Ratio | 82.14% | 580.49% | 53.30% | 5,804.88% | 76.15% |